Bio

Clinical Focus


  • Clinical Genetics
  • Biochemical Genetics

Academic Appointments


Administrative Appointments


  • Associate Program Director, Medical Biochemical Genetics Fellowship Program (2017 - Present)

Honors & Awards


  • Phi Beta Kappa, Northwestern University (2001)
  • Summa cum laude, Northwestern University (2002)
  • Dr. Koch Memorial Scholarship Recipient, National PKU Alliance (2012)

Professional Education


  • Residency:Kaiser Permanente Northern California GME Programs (2011) CA
  • Internship:Kaiser Permanente Northern California GME Programs (2009) CA
  • Board Certification: Clinical Biochemical Genetics, American Board of Medical Genetics and Genomics (2015)
  • Board Certification: Clinical Genetics, American Board of Medical Genetics and Genomics (2013)
  • Fellowship:University of California, San Francisco (UCSF) (2014) CA
  • Residency:University of California, San Francisco (UCSF) (2013) CA
  • Board Certification: Pediatrics, American Board of Pediatrics (2011)
  • Medical Education:University of Illinois at Chicago (2008) IL

Research & Scholarship

Clinical Trials


  • "The MaP Study": Mapping the Patient Journey in MMA and PA Recruiting

    Longitudinal, exploratory, natural history study of patients with MMA due to mut deficiency and PA to characterize the changes in blood disease biomarkers over time and the frequency and severity of clinical events related to their disease.

    View full details

  • A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency Not Recruiting

    A Phase 1/2 Open-label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102. This study is designed to evaluate the safety and tolerability of IV administration of AEB1102 for the treatment of pediatric and adult patients with Arginase I deficiency and hyperargininemia. This study will be conducted in 2 parts: Part 1 (Single Ascending Dose Escalation) and Part 2 (Repeated Dosing). Each part will be preceded by a baseline assessment of arginine levels. All patients who participate in Part 1 may continue AEB1102 dosing in Part 2 if they qualify for continued dosing. A data safety monitoring board (DSMB) will provide independent review of study safety data and recommend whether the sponsor should continue the study as planned, modify the study protocol, or discontinue the study.

    Stanford is currently not accepting patients for this trial. For more information, please contact Spectrum Child Health, 650-724-1175.

    View full details

Publications

All Publications


  • Rare Saposin A deficiency: Novel variant and psychosine analysis. Molecular genetics and metabolism Calderwood, L., Wenger, D. A., Matern, D., Dahmoush, H., Watiker, V., Lee, C. 2019

    Abstract

    Saposin A is a post-translation product of the prosaposin (PSAP) gene that serves as an activator protein of the galactocerebrosidase (GALC) enzyme, and is necessary for the degradation of certain glycosphingolipids. Deficiency of saposin A leads to a clinical picture identical to that of early-infantile Krabbe disease caused by GALC enzyme deficiency. Galactosylsphingosine, also known as psychosine, is a substrate of the GALC enzyme that is known to be elevated in classic Krabbe disease. We present the case of an 18-month-old male with clinical and radiological findings concerning for Krabbe disease who had preserved GALC enzyme activity and negative GALC gene sequencing, but was found to have a homozygous variant, c.257 T > A (p.I86N), in the saposin A peptide of PSAP. Psychosine determination on dried blood spot at 18 months of age was elevated to 12 nmol/L (normal <3 nmol/L). We present this case to add to the literature on the rare diagnosis of atypical Krabbe disease due to saposin A deficiency, to report a novel presumed pathogenic variant within PSAP, and to suggest that individuals with saposin A deficiency may have elevated levels of psychosine, similar to children with classic Krabbe disease due to GALC deficiency.

    View details for DOI 10.1016/j.ymgme.2019.08.001

    View details for PubMedID 31439510

  • Two de novo novel mutations in one SHANK3 allele in a patient with autism and moderate intellectual disability. American journal of medical genetics. Part A Zhu, W., Li, J., Chen, S., Zhang, J., Vetrini, F., Braxton, A., Eng, C. M., Yang, Y., Xia, F., Keller, K. L., Okinaka-Hu, L., Lee, C., Holder, J. L., Bi, W. 2018

    Abstract

    SHANK3 encodes for a scaffolding protein that links neurotransmitter receptors to the cytoskeleton and is enriched in postsynaptic densities of excitatory synapses. Deletions or mutations in one copy of the SHANK3 gene cause Phelan-McDermid syndrome, also called 22q13.3 deletion syndrome, a neurodevelopmental disorder with common features including global developmental delay, absent to severely impaired language, autistic behavior, and minor dysmorphic features. By whole exome sequencing, we identified two de novo novel variants including one frameshift pathogenic variant and one missense variant of unknown significance in a 14-year-old boy with delayed motor milestones, delayed language acquisition, autism, intellectual disability, ataxia, progressively worsening spasticity of the lower extremities, dysmorphic features, short stature, microcephaly, failure to thrive, chronic constipation, intrauterine growth restriction, and bilateral inguinal hernias. Both changes are within the CpG island in exon 21, separated by a 375 bp sequence. Next generation sequencing of PCR products revealed that the two variants are most frequently associated with each other. Sanger sequencing of the cloned PCR products further confirmed that both changes were on a single allele. The clinical presentation in this individual is consistent with other patients with a truncating mutation in exon 21, suggesting that the missense change contributes none or minimally to the phenotypes. This is the first report of two de novo mutations in one SHANK3 allele.

    View details for PubMedID 29423971

  • Biochemical characteristics of newborns with carnitine transporter defect identified by newborn screening in California. Molecular genetics and metabolism Gallant, N. M., Leydiker, K., Wilnai, Y., Lee, C., Lorey, F., Feuchtbaum, L., Tang, H., Carter, J., Enns, G. M., Packman, S., Lin, H. J., Wilcox, W. R., Cederbaum, S. D., Abdenur, J. E. 2017

    Abstract

    Carnitine transporter defect (CTD; also known as systemic primary carnitine deficiency; MIM 212140) is due to mutations in the SLC22A5 gene and leads to extremely low carnitine levels in blood and tissues. Affected individuals may develop early onset cardiomyopathy, weakness, or encephalopathy, which may be serious or even fatal. The disorder can be suggested by newborn screening. However, markedly low newborn carnitine levels can also be caused by conditions unrelated to CTD, such as the low carnitine levels often associated with normal pregnancies and some metabolic disorders occurring in the mother. In order to clarify the biochemical characteristics most useful for identification of CTD in newborns, we examined California Department of Public Health newborn screening data for CTD from 2005 to 12 and performed detailed chart reviews at six metabolic centers in California. The reviews covered 14 cases of newborn CTD, 14 cases of maternal disorders (CTD, 6 cases; glutaric aciduria, type 1, 5; medium-chain acyl CoA dehydrogenase deficiency, 2; and cobalamin C deficiency, 1), and 154 false-positive cases identified by newborn screening. Our results show that newborns with CTD identified by NBS exhibit different biochemical characteristics, compared to individuals ascertained clinically. Newborns with CTD may have NBS dried blood spot free carnitine near the lower cutoff and confirmatory plasma total and free carnitine levels near the normal lower limit, particularly if obtained within two weeks after birth. These findings raise the concern that true cases of CTD may exist that could have been missed by newborn screening. CTD should be considered as a possible diagnosis in cases with suggestive clinical features, even if CTD was thought to be excluded in the newborn period. Maternal plasma total carnitine and newborn urine total carnitine values are the most important predictors of true CTD in newborns. However, biochemical testing alone does not yield a discriminant rule to distinguish true CTD from low carnitine in newborns due to other causes. Because of this biochemical variability and overlap, molecular genetic testing is imperative to confirm CTD in newborns. Additionally, functional testing of fibroblast carnitine uptake remains necessary for cases in which other confirmatory testing is inconclusive. Even with utilization of all available diagnostic testing methods, confirmation of CTD ascertained by NBS remains lengthy and challenging. Incorporation of molecular analysis as a second tier step in NBS for CTD may be beneficial and should be investigated.

    View details for PubMedID 28711408

  • Molecular and clinical spectra of FBXL4 deficiency. Human mutation El-Hattab, A. W., Dai, H., Almannai, M., Wang, J., Faqeih, E. A., Al Asmari, A., Saleh, M. A., Elamin, M. A., Alfadhel, M., Alkuraya, F. S., Hashem, M., Aldosary, M. S., Almass, R., Almutairi, F. B., Alsagob, M., Al-Owain, M., Al-Sharfa, S., Al-Hassnan, Z. N., Al Rahbeeni, Z., Al-Muhaizea, M. A., Makhseed, N., Foskett, G. K., Stevenson, D. A., Gomez-Ospina, N., Lee, C., Boles, R. G., Schrier Vergano, S. A., Wortmann, S. B., Sperl, W., Opladen, T., Hoffmann, G. F., Hempel, M., Prokisch, H., Alhaddad, B., Mayr, J. A., Chan, W., Kaya, N., Wong, L. C. 2017

    Abstract

    F-box and leucine-rich repeat protein 4 (FBXL4) is a mitochondrial protein whose exact function is not yet known. However, cellular studies have suggested that it plays significant roles in mitochondrial bioenergetics, mitochondrial DNA (mtDNA) maintenance, and mitochondrial dynamics. Biallelic pathogenic variants in FBXL4 are associated with an encephalopathic mtDNA maintenance defect syndrome that is a multisystem disease characterized by lactic acidemia, developmental delay, and hypotonia. Other features are feeding difficulties, growth failure, microcephaly, hyperammonemia, seizures, hypertrophic cardiomyopathy, elevated liver transaminases, recurrent infections, variable distinctive facial features, white matter abnormalities and cerebral atrophy found in neuroimaging, combined deficiencies of multiple electron transport complexes, and mtDNA depletion. Since its initial description in 2013, 36 different pathogenic variants in FBXL4 were reported in 50 affected individuals. In this report, we present 37 additional affected individuals and 11 previously unreported pathogenic variants. We summarize the clinical features of all 87 individuals with FBXL4-related mtDNA maintenance defect, review FBXL4 structure and function, map the 47 pathogenic variants onto the gene structure to assess the variants distribution, and investigate the genotype-phenotype correlation. Finally, we provide future directions to understand the disease mechanism and identify treatment strategies. This article is protected by copyright. All rights reserved.

    View details for PubMedID 28940506

  • Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas NATURE GENETICS Piotrowski, A., Xie, J., Liu, Y. F., Poplawski, A. B., Gomes, A. R., Madanecki, P., Fu, C., Crowley, M. R., Crossman, D. K., Armstrong, L., Babovic-Vuksanovic, D., Bergner, A., Blakeley, J. O., Blumenthal, A. L., Daniels, M. S., Feit, H., Gardner, K., Hurst, S., Kobelka, C., Lee, C., Nagy, R., Rauen, K. A., Slopis, J. M., Suwannarat, P., Westman, J. A., Zanko, A., Korf, B. R., Messiaen, L. M. 2014; 46 (2): 182-?

    Abstract

    Constitutional SMARCB1 mutations at 22q11.23 have been found in ∼50% of familial and <10% of sporadic schwannomatosis cases. We sequenced highly conserved regions along 22q from eight individuals with schwannomatosis whose schwannomas involved somatic loss of one copy of 22q, encompassing SMARCB1 and NF2, with a different somatic mutation of the other NF2 allele in every schwannoma but no mutation of the remaining SMARCB1 allele in blood and tumor samples. LZTR1 germline mutations were identified in seven of the eight cases. LZTR1 sequencing in 12 further cases with the same molecular signature identified 9 additional germline mutations. Loss of heterozygosity with retention of an LZTR1 mutation was present in all 25 schwannomas studied. Mutations segregated with disease in all available affected first-degree relatives, although four asymptomatic parents also carried an LZTR1 mutation. Our findings identify LZTR1 as a gene predisposing to an autosomal dominant inherited disorder of multiple schwannomas in ∼80% of 22q-related schwannomatosis cases lacking mutation in SMARCB1.

    View details for DOI 10.1038/ng.2855

    View details for Web of Science ID 000331208300016

    View details for PubMedID 24362817

    View details for PubMedCentralID PMC4352302

  • Teaching NeuroImages: Infant with glutaric aciduria type 1 presenting with infantile spasms and hypsarrhythmia NEUROLOGY Young-Lin, N., Shalev, S., Glenn, O. A., Gardner, M., Lee, C., Wynshaw-Boris, A., Gelfand, A. A. 2013; 81 (24): E182–E183

    Abstract

    A 7-month-old boy with glutaric aciduria type 1 (GA1) presented with 1 week of clustered flexor spasms. Examination revealed mild axial hypotonia without encephalopathy. Video-EEG monitoring revealed hypsarrhythmia and infantile spasms (figure, A). MRI showed acute basal ganglia injury (figure, B). After 3 weeks of prednisolone treatment, 5-month follow-up showed continued resolution of hypsarrhythmia and spasms.

    View details for DOI 10.1212/01.wnl.0000437291.75075.53

    View details for Web of Science ID 000330772300002

    View details for PubMedID 24323445

    View details for PubMedCentralID PMC3863345

  • Homozygosity for a FBN1 missense mutation causes a severe Marfan syndrome phenotype CLINICAL GENETICS HOGUE, J., Lee, C., JELIN, A., Strecker, M. N., Cox, V. A., Slavotinek, A. M. 2013; 84 (4): 392-393

    View details for DOI 10.1111/cge.12073

    View details for Web of Science ID 000324297800018

    View details for PubMedID 23278365

  • The phenotype of Floating-Harbor syndrome: clinical characterization of 52 individuals with mutations in exon 34 of SRCAP ORPHANET JOURNAL OF RARE DISEASES Nikkel, S. M., Dauber, A., de Munnik, S., Connolly, M., Hood, R. L., Caluseriu, O., Hurst, J., Kini, U., Nowaczyk, M. J., Afenjar, A., Albrecht, B., Allanson, J. E., Balestri, P., Ben-Omran, T., Brancati, F., Cordeiro, I., da Cunha, B. S., Delaney, L. A., Destree, A., Fitzpatrick, D., Forzano, F., Ghali, N., Gillies, G., Harwood, K., Hendriks, Y. M., Heron, D., Hoischen, A., Honey, E. M., Hoefsloot, L. H., Ibrahim, J., Jacob, C. M., Kant, S. G., Kim, C. A., Kirk, E. P., Knoers, N. V., Lacombe, D., Lee, C., Lo, I. F., Lucas, L. S., Mari, F., Mericq, V., Moilanen, J. S., Moller, S. T., Moortgat, S., Pilz, D. T., Pope, K., Price, S., Renieri, A., Sa, J., Schoots, J., Silveira, E. L., Simon, M. E., Slavotinek, A., Temple, I. K., van der Burgt, I., de Vries, B. B., Weisfeld-Adams, J. D., Whiteford, M. L., Wierczorek, D., Wit, J. M., Yee, C. F., Beaulieu, C. L., White, S. M., Bulman, D. E., Bongers, E., Brunner, H., Feingold, M., Boycott, K. M. 2013; 8

    Abstract

    Floating-Harbor syndrome (FHS) is a rare condition characterized by short stature, delays in expressive language, and a distinctive facial appearance. Recently, heterozygous truncating mutations in SRCAP were determined to be disease-causing. With the availability of a DNA based confirmatory test, we set forth to define the clinical features of this syndrome.Clinical information on fifty-two individuals with SRCAP mutations was collected using standardized questionnaires. Twenty-four males and twenty-eight females were studied with ages ranging from 2 to 52 years. The facial phenotype and expressive language impairments were defining features within the group. Height measurements were typically between minus two and minus four standard deviations, with occipitofrontal circumferences usually within the average range. Thirty-three of the subjects (63%) had at least one major anomaly requiring medical intervention. We did not observe any specific phenotype-genotype correlations.This large cohort of individuals with molecularly confirmed FHS has allowed us to better delineate the clinical features of this rare but classic genetic syndrome, thereby facilitating the development of management protocols.

    View details for DOI 10.1186/1750-1172-8-63

    View details for Web of Science ID 000319314600001

    View details for PubMedID 23621943

    View details for PubMedCentralID PMC3659005